ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd (TEVA)

16.81
0.32
(1.94%)
終了 11月20日 6:00AM
16.56
-0.25
(-1.49%)
取引時間後: 9:59AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

通貨
16.81
買値
-
売値
-
出来高
8,217,528
16.39 日の範囲 16.86
9.04 52 週間の範囲 19.31
時価総額
前日終値
16.49
始値
16.43
最終取引時間
財務取引量
US$ 136,045,696
VWAP
16.5556
平均取引量 (3 か月)
6,602,207
発行済株式数
1,133,050,214
配当利回り
-
PER
-31.98
1 株当たり利益 (EPS)
-0.49
歳入
15.85B
純利益
-559M

Teva Pharmaceutical Industries Ltd について

Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three se... Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Tel Aviv, Center, Isr
設立
1901
Teva Pharmaceutical Industries Ltd is listed in the Pharmaceutical Preparations sector of the ニューヨーク証券取引所 with ticker TEVA. The last closing price for Teva Pharmaceutical Indu... was US$16.49. Over the last year, Teva Pharmaceutical Indu... shares have traded in a share price range of US$ 9.04 to US$ 19.31.

Teva Pharmaceutical Indu... currently has 1,133,050,214 shares in issue. The market capitalisation of Teva Pharmaceutical Indu... is US$18.68 billion. Teva Pharmaceutical Indu... has a price to earnings ratio (PE ratio) of -31.98.

Teva Pharmaceutical Indu... (TEVA) のオプションフロー概要

全体の流れ

ベアリッシュ

ネットプレミアム

-372k

Calls / Puts

162.50%

買い / 売り

61.54%

OTM / ITM

133.33%

Sweeps比率

14.29%

TEVA 最新ニュース

Teva to Present at the Jefferies London Healthcare Conference

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery...

Teva Statement on European Commission Decision; Company to Appeal

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company intends...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia...

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.58-3.3352501437617.3917.516.15758049216.71638274DR
4-1.3236-7.2991573653318.133619.3116.15715155817.66417027DR
12-1.73-9.3311758360318.5419.3116.15660220717.86430007DR
260.362.1884498480216.4519.3115.62781749417.33180907DR
527.7585.54083885219.0619.319.04902567514.73009105DR
1567.9188.87640449448.919.316.7791989425010.58862558DR
2606.2358.884688090710.5819.316.251042969310.47769577DR

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
NRDYNerdy Inc
US$ 1.25
(25.00%)
6.45M
AIC3 AI Inc
US$ 32.96
(24.19%)
27.94M
DXYZDestiny Tech100 Inc
US$ 45.27
(23.82%)
6.27M
SRFMSurf Air Mobility Inc
US$ 2.19
(22.35%)
568.05k
KUKEKuke Music Holding Limited
US$ 0.2989
(19.56%)
673.38k
DNMRDanimer Scientific Inc
US$ 6.13
(-23.76%)
253.46k
ZEPPZepp Health Corporation
US$ 2.63
(-15.97%)
58.63k
LEVLion Electric Company
US$ 0.2433
(-15.43%)
2.11M
WBXWallbox NV
US$ 0.5749
(-14.21%)
2.15M
FOAFinance of America Companies Inc
US$ 23.65
(-13.37%)
423.09k
NIONIO Inc
US$ 4.64
(-0.64%)
81.56M
PLTRPalantir Technologies Inc
US$ 62.98
(2.81%)
75.85M
NOKNokia Corp
US$ 4.16
(-6.73%)
72.85M
NUNu Holdings Ltd
US$ 13.455
(-1.43%)
58.4M
FFord Motor Company
US$ 11.05
(-1.43%)
53.23M

TEVA Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock